Replies to post #191711 on Biotech Values

[DewDiligence]

I listened to JNP's first-ever* CC and was moderately impressed. JNP is like a gynecological version of SRDX (a company I used to own) that is just getting started wrt internal development projects, but is already cash-flow neutral thanks to Crinone sales and royalties.

I'd be interested in your take on the 1Q15 CC, if you have time to listen.

*Since name and business-model change.